🇺🇸 L-OHP in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 19

Most-reported reactions

1. Neutropenia — 4 reports (21.05%)
2. Altered State Of Consciousness — 2 reports (10.53%)
3. Bone Marrow Toxicity — 2 reports (10.53%)
4. Decreased Appetite — 2 reports (10.53%)
5. Hyperammonaemia — 2 reports (10.53%)
6. Neuropathy Peripheral — 2 reports (10.53%)
7. Renal Impairment — 2 reports (10.53%)
8. Acute Respiratory Distress Syndrome — 1 report (5.26%)
9. Amylase Increased — 1 report (5.26%)
10. Anastomotic Complication — 1 report (5.26%)

Source database →

Frequently asked questions

Is L-OHP approved in United States?

L-OHP does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for L-OHP in United States?

EPS Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.